Eisai and Biogen Win China Approval for LEQEMBI SC
Tokyo, Japan and Cambridge, Massachusetts, USA, September 3, 2026 Eisai Co., Ltd. and Biogen Inc. announced that China’s National...
lecanemab
Advertisement
Eisai and Biogen Advance LEQEMBI Access in Canada
TOKYO and CAMBRIDGE, Mass., August 31, 2026 Eisai and Biogen announced that Canada’s Drug Agency (CDA-AMC) has issued a...
Eisai and Biogen Launch LEQEMBI IQLIK for Alzheimer’s
Tokyo, Japan and Cambridge, Massachusetts, August 25, 2026 Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI IQLIK® (lecanemab-irmb)...
Eisai Advances Alzheimer’s Care with LEQEMBI IQLIK Approval
TOKYO, Japan & CAMBRIDGE, Mass., July 13, 2026 Eisai Co., Ltd. and Biogen Inc. have achieved a major regulatory...
Eisai Showcases Alzheimer’s Research at AAIC 2026 Meeting
TOKYO, June 29, 2026 Eisai Co., Ltd. has announced it will present more than 50 scientific presentations highlighting the...
Advertisements
Eisai and Biogen Report Strong LEQEMBI Long-Term Adherence Data
Copenhagen, Denmark | March 23, 2026 New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb)...
FDA Accepts LEQEMBI sBLA, Expanding At-Home Alzheimer’s Therapy
Tokyo & Cambridge, Massachusetts, January 25, 2026 — Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food...
China Adds LEQEMBI to Insurance List for Early Alzheimer’s
TOKYO and CAMBRIDGE, Mass., December 8, 2025 — Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI® (lecanemab), an...
Eisai Files NDA in Japan for Subcutaneous Leqembi to Expand Alzheimer’s Access
TOKYO & STOCKHOLM — November 28, 2025. Eisai, in partnership with BioArctic, has submitted a New Drug Application (NDA)...
Advertisement
